Drug Profile
Research programme: oral GLP-1 receptor agonists - Merrion/Novo Nordisk
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Merrion Pharmaceuticals; Novo Nordisk
- Class
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in Europe (PO)
- 19 Mar 2012 Preclinical development is ongoing in Denmark
- 16 Jan 2009 Preclinical trials in Type-2 diabetes mellitus in Europe (PO)